An Afghan girl sleeps beneath a mosquito net at her home in Kabul, Afghanistan, July 21, 2016.
By Jessica Berman
Malaria-carrying mosquitoes are becoming resistant to the insecticide used in bed nets to prevent the disease. Researchers say it is important to stay ahead of the resistance to avoid what they are calling a public health catastrophe.
Bed nets treated with inexpensive pyrethroid insecticides are the main defense against biting, malaria-carrying mosquitoes, and they have significantly cut down on the number of cases. The World Health Organization reports malaria infected an estimated 212 million people in 2015, killing some 429,000 of them.
That reflects a 21 percent drop in the incidence of between 2010 and 2015.
But a new study, published in the journal PLoS Genetics, found that the primary mosquito that harbors the parasite in southern Africa, Anopheles funestus, is rapidly becoming resistant to the insecticide. In at least one country, Mozambique, researchers discovered that 100 percent of A. funestus remained alive after direct exposure to the chemical.
Dr Kesetebirhan Admasu, Newly Appointed Chief Executive Officer
The Roll Back Malaria (RBM) Partnership Board is delighted to announce the appointment of Dr Kesetebirhan Admasu to the role of Chief Executive Officer (CEO).
The RBM Board unanimously selected the exceptional Dr. Kesete for the role of RBM CEO at the 4th Partnership Board Meeting, following an extensive global search and selection process supported by executive search firm Egon Zehnder.
Dr Kesete will play a critical role as the global face of the new Partnership on a day-to-day basis, including establishing and leading a new Partnership Management Team and ensuring that regions and countries are empowered to address the global fight against malaria.
Dr. Winnie Mpanju-Shumbusho, Board Chair of the RBM Partnership said “As a champion of innovation, task-shifting and implementation at scale, Dr Kesete has the experience required to lead this global Partnership into a new era and drive momentum to end malaria for good. We are incredibly excited to welcome him on board.”
Dr Kesete will officially commence duties on 1 February 2017 and move into the new RBM offices at the Global Fund in Geneva on 1 March 2017. The RBM Board Leadership will support him in the phased recruitment of remaining members of the new Partnership Management Team over the course of 2017.
“I am excited to join RBM Partnership as the CEO. I look forward to working with all the RBM partners in the effort to relegate malaria into the history books.” – Dr. Kesetebirhan Admasu
This week, the Board of the The Global Fund to Fight AIDS, Tuberculosis and Malaria will meet in Switzerland to decide how much money countries around the world will receive to help the millions of people living with these deadly diseases.
In September, the Global Fund Replenishment raised over $12.9 billion over three years of which Australia committed AUD $220 million.
- TB kills one person every 18 seconds
- AIDS kills one person every 20 seconds
- Malaria kills one person every 30 seconds (mainly children under 5 years old)
It is time to #EndItForGood